← Leaderboards
Scott W Lowe
Sloan-Kettering Inst Can Research
$63,222,126
Attributed
$73,813,720
Total exposure
36
Grants
31
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$74,025,295 · 37
By mechanism
P01$23,252,136 · 14
R01$16,781,272 · 6
U54$13,216,451 · 2
U01$11,402,733 · 2
RF1$3,326,400 · 1
S10$1,842,278 · 6
Top collaborators
- Michel Sadelain6 shared
- Marc Ladanyi5 shared
- David B. Solit5 shared
- Thomas Maxwell Norman3 shared
- Dana Pe'Er3 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Michael Kharas$18,485,709
- Eirini Papapetrou$13,419,805
- Aaron D Viny$3,272,036
- Carl Lekaye$1,309,906
- Andrea Ventura$13,315,692
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsIn VivoTumorOncogenesInsightProgramsMouse ModelMutationTechnologyGenesTumor Suppressor ProteinsPhenotypeGeneticTumorigenesisBiologicalResponseGenomicsMaintenanceBaseCellsTumor Suppressor GenesInnovationLesionRna Interference
Grant awards (136)
Toward development of senolytic CAR T cells$3,326,400
RF1 · FY2025 · AG · contact PI
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis$734,550
R01 · FY2025 · CA · contact PI
Impact of the aging niche on cancer phenotypes probed using mouse cancer models produced by somatic engineering.$507,444
U01 · FY2025 · AG · contact PI
Project 2: Defining and exploiting genetic dependencies in complex karyotype AML$235,096
P50 · FY2025 · CA · contact PI
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis$697,824
R01 · FY2024 · CA · contact PI
Toward development of senolytic CAR T cells$526,481
R01 · FY2024 · AG · contact PI
Impact of the aging niche on cancer phenotypes probed using mouse cancer models produced by somatic engineering.$517,800
U01 · FY2024 · AG · contact PI
Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies$463,686
R01 · FY2024 · CA · contact PI
Systematic characterization of cancer variants using single-cell functional genomics$418,693
R33 · FY2024 · CA
Project 2: Defining and exploiting genetic dependencies in complex karyotype AML$374,760
P50 · FY2024 · CA · contact PI
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis$726,881
R01 · FY2023 · CA · contact PI
Toward development of senolytic CAR T cells$531,078
R01 · FY2023 · AG · contact PI
Impact of the aging niche on cancer phenotypes probed using mouse cancer models produced by somatic engineering.$517,800
U01 · FY2023 · AG · contact PI
Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies$478,329
R01 · FY2023 · CA · contact PI
Systematic characterization of cancer variants using single-cell functional genomics$431,914
R33 · FY2023 · CA
Project 2: Defining and exploiting genetic dependencies in complex karyotype AML$311,223
P50 · FY2023 · CA · contact PI
Project 5: Tumor Suppressor and Tumor Maintenance Genes$617,817
P01 · FY2022 · CA · contact PI
Toward development of senolytic CAR T cells$535,583
R01 · FY2022 · AG · contact PI
Impact of the aging niche on cancer phenotypes probed using mouse cancer models produced by somatic engineering.$517,800
U01 · FY2022 · AG · contact PI
Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies$478,329
R01 · FY2022 · CA · contact PI
Systematic characterization of cancer variants using single-cell functional genomics$440,728
R33 · FY2022 · CA
Project 2: Defining and exploiting genetic dependencies in complex karyotype AML$367,707
P50 · FY2022 · CA · contact PI
Project 4: Lung Cancer Drivers and Dependencies as Therapeutic Targets$282,446
P01 · FY2022 · CA · contact PI
Project 5: Tumor Suppressor and Tumor Maintenance Genes$630,426
P01 · FY2021 · CA · contact PI
Toward development of senolytic CAR T cells$539,995
R01 · FY2021 · AG · contact PI
Impact of the aging niche on cancer phenotypes probed using mouse cancer models produced by somatic engineering.$537,050
U01 · FY2021 · AG · contact PI
Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies$488,090
R01 · FY2021 · CA · contact PI
Project 2: Defining and exploiting genetic dependencies in complex karyotype AML$384,164
P50 · FY2021 · CA · contact PI
Project 4: Mechanisms of wild-type and mutant p53 action in vivo$355,831
P01 · FY2021 · CA · contact PI
Project 4: Lung Cancer Drivers and Dependencies as Therapeutic Targets$288,211
P01 · FY2021 · CA · contact PI
Project 5: Tumor Suppressor and Tumor Maintenance Genes$630,426
P01 · FY2020 · CA · contact PI
Toward development of senolytic CAR T cells$544,277
R01 · FY2020 · AG · contact PI
Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies$488,090
R01 · FY2020 · CA · contact PI
Project 4: Mechanisms of wild-type and mutant p53 action in vivo$355,831
P01 · FY2020 · CA · contact PI
Project 4: Lung Cancer Drivers and Dependencies as Therapeutic Targets$288,211
P01 · FY2020 · CA · contact PI
MSKCC Pilot Center for Precision Disease Modeling$2,038,557
U54 · FY2019 · OD · contact PI
Project 5: Tumor Suppressor and Tumor Maintenance Genes$615,496
P01 · FY2019 · CA · contact PI
The impact of chromosome 17p lesions on leukemogeneis and therapy response$398,509
R01 · FY2019 · CA · contact PI
Project 4: Mechanisms of wild-type and mutant p53 action in vivo$345,156
P01 · FY2019 · CA · contact PI
Project 4: Lung Cancer Drivers and Dependencies as Therapeutic Targets$276,293
P01 · FY2019 · CA · contact PI
Exploiting SS18-SSX chromatin localizing mechanisms and modifiers for synovial sarcoma treatment$3,291,481
U54 · FY2018 · CA · contact PI
MSKCC Pilot Center for Precision Disease Modeling$1,996,560
U54 · FY2018 · OD · contact PI
Project 5: Tumor Suppressor and Tumor Maintenance Genes$632,982
P01 · FY2018 · CA · contact PI
RNAi Tools for Breast Cancer Research$416,470
P01 · FY2018 · CA · contact PI
The impact of chromosome 17p lesions on leukemogeneis and therapy response$402,371
R01 · FY2018 · CA · contact PI
Project 4: Mechanisms of wild-type and mutant p53 action in vivo$355,830
P01 · FY2018 · CA · contact PI
Project 4: Lung Cancer Drivers and Dependencies as Therapeutic Targets$284,838
P01 · FY2018 · CA · contact PI
MSKCC Pilot Center for Precision Disease Modeling$1,896,733
U54 · FY2017 · OD · contact PI
A scalable platform for target validation in GEMM models of gastrointestinal malignancies.$641,206
R01 · FY2017 · CA · contact PI
RNAi Tools for Breast Cancer Research$415,911
P01 · FY2017 · CA · contact PI
The impact of chromosome 17p lesions on leukemogeneis and therapy response$402,371
R01 · FY2017 · CA · contact PI
Project 4: Mechanisms of wild-type and mutant p53 action in vivo$370,833
P01 · FY2017 · CA · contact PI
MSKCC Pilot Center for Precision Disease Modeling$1,996,560
U54 · FY2016 · OD · contact PI
A scalable platform for target validation in GEMM models of gastrointestinal malignancies.$648,617
R01 · FY2016 · CA · contact PI
Project 5$644,371
P01 · FY2016 · CA · contact PI
RNAi Tools for Breast Cancer Research$419,261
P01 · FY2016 · CA · contact PI
The impact of chromosome 17p lesions on leukemogeneis and therapy response$402,371
R01 · FY2016 · CA · contact PI
Lung Cancer Drivers and Dependencies as Therapeutic Targets$365,049
P01 · FY2016 · CA · contact PI
MSKCC Pilot Center for Precision Disease Modeling$1,996,560
U54 · FY2015 · OD · contact PI
A scalable platform for target validation in GEMM models of gastrointestinal malignancies.$674,831
R01 · FY2015 · CA · contact PI
Project 5$643,512
P01 · FY2015 · CA · contact PI
RAS Induced Senescence and Tumor Suppression$435,000
R56 · FY2015 · AG · contact PI
RNAi Tools for Breast Cancer Research$419,540
P01 · FY2015 · CA · contact PI
p53 and Chemosensitivity in a Mouse Lymphoma Model$414,182
P01 · FY2015 · CA · contact PI
The impact of chromosome 17p lesions on leukemogeneis and therapy response$402,371
R01 · FY2015 · CA · contact PI
Lung Cancer Drivers and Dependencies as Therapeutic Targets$365,049
P01 · FY2015 · CA · contact PI
Project 5$632,154
P01 · FY2014 · CA · contact PI
RNAi Tools for Breast Cancer Research$417,274
P01 · FY2014 · CA · contact PI
p53 and Chemosensitivity in a Mouse Lymphoma Model$402,181
P01 · FY2014 · CA · contact PI
Lung Cancer Drivers and Dependencies as Therapeutic Targets$357,605
P01 · FY2014 · CA · contact PI
Ras Induced Senescence and Tumor Suppression$174,000
R01 · FY2014 · AG · contact PI
Identifying driver mutations and tumor dependencies by comparative oncogenomics.$850,689
U01 · FY2013 · CA · contact PI
CyTOF ICP-TOF-MS Model C5$600,000
S10 · FY2013 · OD · contact PI
Project 5$598,168
P01 · FY2013 · CA · contact PI
p53 and Chemosensitivity in a Mouse Lymphoma Model$390,249
P01 · FY2013 · CA · contact PI
Lung Cancer Drivers and Dependencies as Therapeutic Targets$343,146
P01 · FY2013 · CA · contact PI
Ras Induced Senescence and Tumor Suppression$337,171
R01 · FY2013 · AG · contact PI
Identifying driver mutations and tumor dependencies by comparative oncogenomics.$907,845
U01 · FY2012 · CA · contact PI
Tumor Suppression$622,362
P01 · FY2012 · CA · contact PI
p53 and Chemosensitivity in a Mouse Lymphoma Model$415,443
P01 · FY2012 · CA · contact PI
Lung Cancer Drivers and Dependencies as Therapeutic Targets$372,966
P01 · FY2012 · CA · contact PI
Ras Induced Senescence and Tumor Suppression$356,794
R01 · FY2012 · AG · contact PI
Identifying driver mutations and tumor dependencies by comparative oncogenomics.$841,281
U01 · FY2011 · CA · contact PI
Tumor Suppression$674,249
P01 · FY2011 · CA · contact PI
Mosaic Mouse Models of Human Cancer$473,694
P01 · FY2011 · CA · contact PI
Ras Induced Senescence and Tumor Suppression$353,216
R01 · FY2011 · AG · contact PI
Identifying driver mutations and tumor dependencies by comparative oncogenomics.$871,519
U01 · FY2010 · CA · contact PI
Tumor Suppression$753,240
P01 · FY2010 · CA · contact PI
Mosaic Mouse Models of Human Cancer$430,396
P01 · FY2010 · CA · contact PI
p53 and Chemosensitivity in a Mouse Lymphoma Model$414,058
P01 · FY2010 · CA · contact PI
Ras Induced Senescence and Tumor Suppression$353,133
R01 · FY2010 · AG · contact PI
Identifying driver mutations and tumor dependencies by comparative oncogenomics.$821,775
U01 · FY2009 · CA · contact PI
Tumor Suppression$713,324
P01 · FY2009 · CA · contact PI
Mosaic Mouse Models of Human Cancer$408,039
P01 · FY2009 · CA · contact PI
p53 and Chemosensitivity in a Mouse Lymphoma Model$406,228
P01 · FY2009 · CA · contact PI
Ras Induced Senescence and Tumor Suppression$344,400
R01 · FY2009 · AG · contact PI
Making hypomorphic tumor supressors in vivo using RNAi$893,063
U01 · FY2008 · CA · contact PI
Tumor Suppression$718,040
P01 · FY2008 · CA · contact PI
Mosaic Mouse Models of Human Cancer$411,198
P01 · FY2008 · CA · contact PI
RAS INDUCED SENESCENCE AND TUMOR PROGRESSION$409,452
R01 · FY2008 · AG · contact PI
p53 and Chemosensitivity in a Mouse Lymphoma Model$394,677
P01 · FY2008 · CA · contact PI
Making hypomorphic tumor supressors in vivo using RNAi$20,988
U01 · FY2008 · CA · contact PI
Making hypomorphic tumor supressors in vivo using RNAi$884,222
U01 · FY2007 · CA · contact PI
Tumor Suppression$646,450
P01 · FY2007 · CA · contact PI
Nordion Research Irradiator$425,826
S10 · FY2007 · RR · contact PI
RAS INDUCED SENESCENCE AND TUMOR PROGRESSION$405,752
R01 · FY2007 · AG · contact PI
p53 and Chemosensitivity in a Mouse Lymphoma Model$403,944
P01 · FY2007 · CA · contact PI
Mosaic Mouse Models of Human Cancer$370,366
P01 · FY2007 · CA · contact PI
Making hypomorphic tumor supressors in vivo using RNAi$60,992
U01 · FY2007 · CA · contact PI
Making hypomorphic tumor supressors in vivo using RNAi$883,896
U01 · FY2006 · CA · contact PI
Animal Facility Renovations$647,000
G20 · FY2006 · RR · contact PI
RAS INDUCED SENESCENCE AND TUMOR PROGRESSION$498,501
R01 · FY2006 · AG · contact PI
p53 and Chemosensitivity in a Mouse Lymphoma Model$330,417
P01 · FY2006 · CA · contact PI
Xenogen Bioluminescent Animal Imager$211,575
S10 · FY2006 · RR · contact PI
XENOGEN BIOLUMINESCENT ANIMAL IMAGER: CANCER$148,102
S10 · FY2006 · RR · contact PI
Scientific Reagents$115,748
P01 · FY2006 · CA · contact PI
XENOGEN BIOLUMINESCENT ANIMAL IMAGER$63,473
S10 · FY2006 · RR · contact PI
Making hypomorphic tumor supressors in vivo using RNAi$40,622
U01 · FY2006 · CA · contact PI
Making hypomorphic tumor supressors in vivo using RNAi$877,948
U01 · FY2005 · CA
RAS INDUCED SENESCENCE AND TUMOR PROGRESSION$498,514
R01 · FY2005 · AG
RAS INDUCED SENESCENCE AND TUMOR PROGRESSION$35,107
R01 · FY2005 · AG
Making hypomorphic tumor supressors in vivo using RNAi$849,999
U01 · FY2004 · CA
RAS INDUCED SENESCENCE AND TUMOR PROGRESSION$390,832
R01 · FY2004 · AG
RAS INDUCED SENESCENCE AND TUMOR PROGRESSION$344,863
R01 · FY2003 · AG
Flow Cytometer$393,302
S10 · FY2002 · RR
RAS INDUCED SENESCENCE AND TUMOR PROGRESSION$334,902
R01 · FY2002 · AG
CORE--FLOW CYTOMETRY$78,870
P30 · FY2002 · CA
TUMOR SUPPRESSION$0
P01 · FY2002 · CA
RAS INDUCED SENESCENCE AND TUMOR PROGRESSION$325,236
R01 · FY2001 · AG
CANCER THERAPY$228,401
P01 · FY2001 · CA
RAS INDUCED SENESCENCE AND TUMOR PROGRESSION$97,706
R01 · FY2001 · AG
CORE--FLOW CYTOMETRY$78,870
P30 · FY2001 · CA
CORE--FLOW CYTOMETRY$0
P30 · FY2001 · CA
CANCER THERAPY$374,147
P01 · FY2000 · CA
RAS INDUCED SENESCENCE AND TUMOR PROGRESSION$315,853
R01 · FY2000 · AG
CORE--FLOW CYTOMETRY$0
P30 · FY2000 · CA